info@ease-med-control.com
Scientists
Scientists team
ANDREAS
HABENICHT
M.D.; Professor of Internal Medicine and Endocrinology
COFOUNDER and Managing Director
About Andreas:
Andreas is presently a principal investigator and group leader at the IPEK of the University Clinic of the Ludwig-Maximilians-University Munich in Germany. His current research goal is to identify how the nervous system interacts with the vascular and immune systems to promote clinically significant diseases.
Andreas obtained his M.D. degree at the University of Heidelberg in 1977. After receiving a postdoctoral fellowship from the German Research Council he conducted research at the Medical School of the University of Washington in Seattle on molecular mechanisms of atherosclerosis. After returning to Heidelberg in 1980 and subsequent training in Internal Medicine, he supervised the emergency outpatient clinic of the Department of Internal Medicine of the University. He served in various clinical positions including being the consulting internist at the Department of Surgery. In addition to his work at the University Hospital, he worked during weekends as the emergency physician for the city of Heidelberg. In 2000 he was appointed director of the Institute for Vascular Medicine at the Medical School of the Friedrich-Schiller-University in Jena to continue his work on the immunology of atherosclerosis. During his tenure in Jena, he discovered artery tertiary lymphoid organs in the connective tissue coat of arteries and helped to identify these immune cell aggregates as regulators of atherosclerosis. In 2011, he moved to the IPEK at the University Clinic of the Ludwig-Maximilians-University in Munich. Andreas together with Changjun Yin and Sarajo Mohanta discovered that artery tertiary lymphoid organs in atherosclerosis establish a neuroimmune interface (NICI) connecting the diseased arterial wall with the peripheral and central nervous systems. Subsequent studies demonstrated that the classical complement cascade participates in atherosclerosis-associated inflammation involving direct interactions of Apolipoprotein E with the complement-initiating molecule C1q.
Andreas is presently a principal investigator and group leader at the IPEK of the University Clinic of the Ludwig-Maximilians-University Munich in Germany. His current research goal is to identify how the nervous system interacts with the vascular and immune systems to promote clinically significant diseases.
Andreas obtained his M.D. degree at the University of Heidelberg in 1977. After receiving a postdoctoral fellowship from the German Research Council he conducted research at the Medical School of the University of Washington in Seattle on molecular mechanisms of atherosclerosis. After returning to Heidelberg in 1980 and subsequent training in Internal Medicine, he supervised the emergency outpatient clinic of the Department of Internal Medicine of the University. He served in various clinical positions including being the consulting internist at the Department of Surgery. In addition to his work at the University Hospital, he worked during weekends as the emergency physician for the city of Heidelberg. In 2000 he was appointed director of the Institute for Vascular Medicine at the Medical School of the Friedrich-Schiller-University in Jena to continue his work on the immunology of atherosclerosis. During his tenure in Jena, he discovered artery tertiary lymphoid organs in the connective tissue coat of arteries and helped to identify these immune cell aggregates as regulators of atherosclerosis. In 2011, he moved to the IPEK at the University Clinic of the Ludwig-Maximilians-University in Munich. Andreas together with Changjun Yin and Sarajo Mohanta discovered that artery tertiary lymphoid organs in atherosclerosis establish a neuroimmune interface (NICI) connecting the diseased arterial wall with the peripheral and central nervous systems. Subsequent studies demonstrated that the classical complement cascade participates in atherosclerosis-associated inflammation involving direct interactions of Apolipoprotein E with the complement-initiating molecule C1q.
SARAJO
MOHANTA
Ph.D.; Principal Investigator
MOHANTA
Ph.D.; Principal Investigator
COFOUNDER
About Sarajo:
Sarajo (Saroj) is currently a principal investigator at the Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich. His current research goal is to identify how the nervous system interacts with the vascular and immune systems to affect clinically significant diseases including atherosclerosis.
Saroj studied Veterinary Medicine at Orissa University of Agriculture and Technology in India and obtained his Master degree in Biomedicine from the University of Portsmouth in the United Kingdom. He received his Ph.D. in Immunology at the Friedrich-Schiller-University Jena after receiving graduate training as a master student at the Leibniz Graduate School of Aging Jena and the Institute for Vascular Medicine at the University Hospital of the Friedrich-Schiller-University Jena Germany. Prior to joining IPEK in 2015, Saroj was a postdoctoral fellow of the German Research Foundation at the Leibniz Institute for Aging Research, Jena working on the role of lymphotoxin beta receptor in atherosclerosis from 2013-2015. Saroj obtained a grant from the German Research Council (DFG) to study the interaction of the diseased arterial wall and the peripheral nervous system (http://gepris.dfg.de/gepris/person/283135141). Saroj together with Andreas Habenicht observed that artery tertiary lymphoid organs form a NICI connecting the atherosclerotic arterial wall with the peripheral and central nervous systems. These studies led to the discovery of Atherosclerosis Brain Circuits (ABCs). His work led the groundwork for an international collaboration of four European groups within the ERA-CVD 2017 call beginning in January 2019 (https://www.era-cvd.eu/286.php).
Sarajo (Saroj) is currently a principal investigator at the Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich. His current research goal is to identify how the nervous system interacts with the vascular and immune systems to affect clinically significant diseases including atherosclerosis.
Saroj studied Veterinary Medicine at Orissa University of Agriculture and Technology in India and obtained his Master degree in Biomedicine from the University of Portsmouth in the United Kingdom. He received his Ph.D. in Immunology at the Friedrich-Schiller-University Jena after receiving graduate training as a master student at the Leibniz Graduate School of Aging Jena and the Institute for Vascular Medicine at the University Hospital of the Friedrich-Schiller-University Jena Germany. Prior to joining IPEK in 2015, Saroj was a postdoctoral fellow of the German Research Foundation at the Leibniz Institute for Aging Research, Jena working on the role of lymphotoxin beta receptor in atherosclerosis from 2013-2015. Saroj obtained a grant from the German Research Council (DFG) to study the interaction of the diseased arterial wall and the peripheral nervous system (http://gepris.dfg.de/gepris/person/283135141). Saroj together with Andreas Habenicht observed that artery tertiary lymphoid organs form a NICI connecting the atherosclerotic arterial wall with the peripheral and central nervous systems. These studies led to the discovery of Atherosclerosis Brain Circuits (ABCs). His work led the groundwork for an international collaboration of four European groups within the ERA-CVD 2017 call beginning in January 2019 (https://www.era-cvd.eu/286.php).
CHANGJUN
YIN
Ph.D.; Principal Investigator
YIN
Ph.D.; Principal Investigator
COFOUNDER
About Changjun:
Changjun is presently a principal investigator at the IPEK at the University Clinic of the Ludwig-Maximilians-University Munich in Germany. Changjun´s current research goal is to identify the interaction of peripheral vascular diseases and brain neurodegenerative diseases, i.e. atherosclerosis and Alzheimer´s Disease. In addition, Changjun is interested in the possibility that atherosclerosis is an autoimmune disease.
Changjun obtained his Bachelor and Master degrees in Biochemistry and Molecular Biology at Huazhong Agricultural University, Wuhan, China in 2007 and 2009, respectively. He moved to the Institute for Vascular Medicine at the University Hospital of the Friedrich-Schiller-University and the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) - in Jena, Germany to pursue his Ph.D. degree. Changjun obtained his Ph.D. degree in immunology in 2013. He subsequently moved to the IPEK for postdoctoral training. In 2015, Changjun obtained a research grant from the German Research Foundation (DFG) to study brain immune injury in aged hyperlipidemic mice (http://gepris.dfg.de/gepris/person/270636936). Changjun led an international research collaboration to demonstrate that Apolipoprotein E directly interacts with the classical complement cascade-initiating molecule C1q and that this interaction participates in several clinically significant diseases, i.e. atherosclerosis and Alzheimer´s Disease.
Changjun is presently a principal investigator at the IPEK at the University Clinic of the Ludwig-Maximilians-University Munich in Germany. Changjun´s current research goal is to identify the interaction of peripheral vascular diseases and brain neurodegenerative diseases, i.e. atherosclerosis and Alzheimer´s Disease. In addition, Changjun is interested in the possibility that atherosclerosis is an autoimmune disease.
Changjun obtained his Bachelor and Master degrees in Biochemistry and Molecular Biology at Huazhong Agricultural University, Wuhan, China in 2007 and 2009, respectively. He moved to the Institute for Vascular Medicine at the University Hospital of the Friedrich-Schiller-University and the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) - in Jena, Germany to pursue his Ph.D. degree. Changjun obtained his Ph.D. degree in immunology in 2013. He subsequently moved to the IPEK for postdoctoral training. In 2015, Changjun obtained a research grant from the German Research Foundation (DFG) to study brain immune injury in aged hyperlipidemic mice (http://gepris.dfg.de/gepris/person/270636936). Changjun led an international research collaboration to demonstrate that Apolipoprotein E directly interacts with the classical complement cascade-initiating molecule C1q and that this interaction participates in several clinically significant diseases, i.e. atherosclerosis and Alzheimer´s Disease.
